Spotlight On... Mylan gets one step closer to finally challenging Glaxo's Advair; Mylan appoints new commercial chief; Amgen, UCB osteoporosis contender shines in postmenopausal patients; and more...

Generic competition to GlaxoSmithKline ($GSK) respiratory behemoth Advair could finally be on the horizon, and Mylan ($MYL) wants to make sure it gets a piece of the med's blockbuster revenues. Friday, the company announced that the FDA had accepted its application for a copy of the blockbuster, with a decision date set for the end of March. Mylan joins Hikma and Novartis' ($NVS) Sandoz, which have already made FDA submissions. Release

> Mylan ($MYL) has appointed Anthony Mauro as its new chief commercial officer. Release

> Amgen ($AMGN) and UCB's osteoporosis candidate, romosozumab, showed in a late-stage study that it could reduce the incidence of new vertebral fracture in postmenopausal patients with the disease. Report

> Endo ($ENDP) has launched Belbuca buccal film, a treatment for chronic pain management. Release

> Merck KGaA has launched its "More Than a Mother" campaign in partnership with Uganda's health ministry to raise awareness about preventing infertility in the country. Report

And Finally... Spending more on government-sponsored drug studies could encourage label expansions and cut down on off-label marketing. More

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.